

#### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Thomas Pavelko on 10/21/08.

The application has been amended as follows:

In claim 28, line 2, "myrisityl" has been substituted by --myristyl --.

In claim 28, line 3, "myrisityl" has been substituted by --myristyl --.

In claim 29, line 3, "and stearyl palmitate." has been substituted by --, stearyl palmitate and at least one other component selected from the group consisting of myristyl myristate, palmityl stearate, stearyl stearate, stearyl arachidate, and stearyl behenate.--.

*42*  
In claim 41, line 2, "comprising:" has been substituted by --consisting of:--.

In claim 43, line 1, "40" has been substituted by --41--.

In claim 43, line 2, "comprising:" has been substituted by --consisting of:--.

In claim 51, line 2, "comprising:" has been substituted by --consisting of:--.

*43*  
In the specification page 3, line 23, please add --BRIEF DESCRIPTION OF THE FIGURES-- as a new heading.